2025 Event Agenda
Our 2025 Agenda Addressed Barriers in:
Potency and Predictivity: Build assays that go beyond basic functionality and satisfy regulators to give you greater confidence in clinical outcomes.
Method Validation and Transfer: Avoid costly delays when scaling assays across sites and partners by implementing lessons-learned by Bayer and Novartis.
Regulatory Confidence: Gain insider insights into the latest FDA, EMA, and USP requirements, to approach regulatory interactions with clarity and confidence
Product Characterization: Strengthen the identity, sterility, and safety of your assays to deliver reproducible and comparable results, ahead of commercialization.
Cell therapies continue to evolve rapidly, and the clear need for robust analytics to understand and characterize cell therapy drug products continues to grow. A meeting like this is crucial to exchange and share the ideas and information needed to accelerate bringing these therapies to patients
Head, Analytical Development & Testing, Genentech, 2025 Speaker
Having trouble downloading the brochure? Let us know and we'll email it to you instead.
The 2025 Speaking Companies:
